Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough lymphomas? early trial of NB02 begins

NCT ID NCT07114367

Disease control Sponsor: NOBO Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new drug called NB02 (posseltinib) in 9 adults with certain types of Non-Hodgkin lymphoma (follicular, mantle cell, or marginal zone) that have returned or not responded to at least two prior treatments. The main goals are to find a safe dose and check for side effects, while also looking for signs that the drug might fight the cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NB02 (posseltinib)
What this could lead to
If this works, it could point toward a new treatment option for people with certain types of Non-Hodgkin lymphoma that have not responded to other therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 9 participants, so it is mainly checking safety and dosing. It is too soon to know if the drug will effectively shrink tumors or help patients feel better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 9 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 19 to 80 years. 2. Patients must voluntarily agree to participate in the study and provide written informed consent prior to any study-related procedures. 3. Patients with histologically confirmed follicular lymphoma, mantle cell lymphoma or marginal zone lymphoma. 4. relapsed/refractory Patients who have received more than two prior lines of therapy. 5. Measurable disease based on Lugano classification. 6. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. 7. Adequate organ function including: Exclusion Criteria: 1. Previous treatment with NB02 (poseltinib). 2. Patients who have experienced progression on BTKi mono or BTKi containing regimen (However, patients who discontinued treatment due to adverse-effect-related intolerance or for economic or social reasons remain eligible for enrollment). 3. Unable to take oral medication. 4. Inability to comply with study and follow-up procedures. 5. Concurrent use of other investigational drugs or enrollment in another clinical trial within 4 weeks prior to study drug administration. 6. Patients who have previously been treated with NB02 (poseltinib) or any other BTK inhibitors (e.g., ibrutinib, acalabrutinib, zanubrutinib). 7. Known HIV, HCV and HBV infection with active diseases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Follicular lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

follicular lymphoma lymphoma mantle cell lymphoma marginal zone lymphoma non-Hodgkin lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non Hodgkin lymphoma (NHL)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Catholic univ of Yeouido St Mary's Hospital

    RECRUITING

    Seoul, South Korea

  • Chonnam National University Hwasun Hospital

    RECRUITING

    Hwasun, South Korea

  • Samsung Medical Center

    RECRUITING

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    RECRUITING

    Seongnam, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, South Korea

  • Ulsan University Hospital

    RECRUITING

    Ulsan, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.